At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Curcumindrug
Likely dose
Curcumin 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis
In Brief
A Phase 2 clinical trial evaluating Curcumin for Primary Sclerosing Cholangitis. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether curcumin, a drug and naturally-occurring plant compound, is safe and effective in the treatment of primary sclerosing cholangitis (PSC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sclerosing Cholangitis
CountriesUnited States
CollaboratorsEuroPharma, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartJun 2017
Primary CompletionNov 2018
Study CompletionJan 2019
TodayJul 2026
First PostedNov 30, 2016
Enrollment StartJun 9, 2017
Primary CompletionNov 16, 2018
Study CompletionJan 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.6 years ago
Interventions
Curcumindrug
Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.